This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

This study has been completed.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: March 5, 2012
Last updated: November 1, 2016
Last verified: November 2016
This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma. Stage 1 is the dose escalation part of the study. Stage 2, patients will receive GDC-0084 at a recommended dose for future studies.

Condition Intervention Phase
Glioblastoma, Glioma Drug: GDC-0084 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Safety: Incidence of adverse events [ Time Frame: approximately 2 years ]
  • Maximum tolerated dose (MTD) [ Time Frame: approximately 1 year ]

Secondary Outcome Measures:
  • Pharmacokinetics: Area under the concentration-time curve [ Time Frame: Pre- and post-dose Days 1, 8, 15, 22 and 29 Cycle 1, Day 1 every following Cycle until 30 days after the last dose of study drug ]
  • Best overall response rate, tumor assessments according to Response Assessment in Neuro-Oncology (RANO) [ Time Frame: approximately 2 years ]
  • Duration of response [ Time Frame: approximately 2 years ]
  • Progression-free survival [ Time Frame: approximately 2 years ]

Enrollment: 29
Study Start Date: April 2012
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Arm Drug: GDC-0084
Multiple doses


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Interval of at least 12 weeks from completion of adjuvant radiotherapy for gliomas to study entry
  • Karnofsky Performance Status of >/= 70 at screening
  • Confirmed measurable disease per RANO
  • Adequate hematologic and organ function

Patients enrolled in Stage 1:

  • Histologically documented recurrent or progressive high-grade gliomas (WHO Grade III-IV)
  • Prior treatment with at least one regimen for gliomas (radiotherapy with or without chemotherapy for Grade III gliomas and radiotherapy with chemotherapy for Grade IV gliomas) and/or not considered to be a candidate for regimens known to provide clinical benefit

Patients enrolled in Stage 2:

  • Histologically documented recurrent or progressive glioblastoma (WHO Grade IV gliomas)
  • Prior treatment with one or two regimens for glioblastoma (with the initial regimen consisting of radiotherapy with chemotherapy)

Exclusion Criteria:

  • Treatment with anti-tumor therapy (approved or experimental) within 4 weeks prior to initiation of study drug
  • Requirement for anticoagulants such as warfarin or any other warfarin-derivative anticoagulants; low-molecular-weight heparin is permitted
  • Any contraindication to MRI examination
  • Evidence of Grade >/= 1 intracranial hemorrhage
  • Active congestive heart failure or ventricular arrhythmia requiring medication
  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse or cirrhosis
  • Unresolved toxicity from prior therapy with the exception of lymphopenia (for patients with prior temozolomide) and alopecia
  • Pregnant or lactating women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01547546

United States, California
Los Angeles, California, United States, 90095
United States, Massachusetts
Boston, Massachusetts, United States, 02114
Boston, Massachusetts, United States, 02115
United States, Texas
Houston, Texas, United States, 77030
Barcelona, Spain, 08035
Sponsors and Collaborators
Genentech, Inc.
Study Director: Clinical Trials Genentech, Inc.
  More Information

Responsible Party: Genentech, Inc. Identifier: NCT01547546     History of Changes
Other Study ID Numbers: GO28070
2011-004479-35 ( EudraCT Number )
Study First Received: March 5, 2012
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue processed this record on August 22, 2017